- Home
- BLTE
BLTE
Belite Bio Inc
as of 10-23-2026 12:40pm EST
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.0B | IPO Year: | 2021 |
| Target Price: | $228.89 | AVG Volume (30 days): | 133.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $90.83 - $200.00 | Next Earning Date: | 11-09-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered BLTE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Belite Bio Inc (BLTE)
Chief Medical Officer
Avg Cost/Share
$166.92
Shares
500
Total Value
$82,658.89
Owned After
14,800
Chief Executive Officer
Avg Cost/Share
$196.39
Shares
26,000
Total Value
$5,110,485.74
Owned After
70,134
Chief Financial Officer
Avg Cost/Share
$196.33
Shares
17,962
Total Value
$3,528,138.59
Owned After
37,680
Chief Executive Officer
Avg Cost/Share
$186.83
Shares
74,435
Total Value
$13,972,062.76
Owned After
70,134
Chief Financial Officer
Avg Cost/Share
$186.81
Shares
49,433
Total Value
$9,275,389.26
Owned After
37,680
Chief Executive Officer
Avg Cost/Share
$180.29
Shares
365
Total Value
$65,827.11
Owned After
70,134
Chief Financial Officer
Avg Cost/Share
$180.29
Shares
367
Total Value
$66,187.11
Owned After
37,680
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Scholl Hendrik Peter | BLTE | Chief Medical Officer | Oct 1, 2026 | Sell | $166.92 | 500 | $82,658.89 | 14,800 | |
| Lin Yu-Hsin | BLTE | Chief Executive Officer | Sep 8, 2026 | Sell | $196.39 | 26,000 | $5,110,485.74 | 70,134 | |
| Chuang Hao-Yuan | BLTE | Chief Financial Officer | Sep 8, 2026 | Sell | $196.33 | 17,962 | $3,528,138.59 | 37,680 | |
| Lin Yu-Hsin | BLTE | Chief Executive Officer | Sep 4, 2026 | Sell | $186.83 | 74,435 | $13,972,062.76 | 70,134 | |
| Chuang Hao-Yuan | BLTE | Chief Financial Officer | Sep 4, 2026 | Sell | $186.81 | 49,433 | $9,275,389.26 | 37,680 | |
| Lin Yu-Hsin | BLTE | Chief Executive Officer | Aug 12, 2026 | Sell | $180.29 | 365 | $65,827.11 | 70,134 | |
| Chuang Hao-Yuan | BLTE | Chief Financial Officer | Aug 12, 2026 | Sell | $180.29 | 367 | $66,187.11 | 37,680 |
Compare BLTE vs Leading Stocks
See how BLTE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BLTE Belite Bio Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.